{
  "id": 379387,
  "title": "Biohaven earnings set to show cash burn ahead of epilepsy data",
  "url": "https://urgent.news/2026/08/09/biohaven-earnings-set-to-show-cash-burn-ahead-of-epilepsy-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-09T13:36:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/biohaven-earnings-set-to-show-cash-burn-ahead-of-epilepsy-data-93CH-4847742"
  },
  "original_language": "en",
  "account": "Biohaven Pharmaceutical Holding Co Ltd is set to release its second-quarter earnings report on Monday, with analysts closely monitoring the company's cash burn rate as it prepares to present crucial epilepsy drug data later this year. The biotech, operating at a loss, reported a narrowed loss of 75 cents per share for the quarter ending June, down from an 88-cent loss in the first quarter. As of March 31, Biohaven had $351.8 million in cash and equivalents, and investors will scrutinize how swiftly the New Haven, Conn.-based company depletes this reserve. Despite a lackluster stock performance, analysts rate Biohaven as a buy with a mean price target of $22.93, suggesting a 56% upside. The company's loss is expected to decline by over 61% year-over-year, reflecting cost-cutting measures implemented in late 2025. Biohaven's focus remains on execution and cash management rather than top-line growth, as it has not generated revenue while advancing its pipeline through clinical trials. The company announced a restructuring in November 2025 aimed at reducing annual direct R&D spend by approximately 60%, and Monday's report will reveal whether these savings are being realized. Opakalim, Biohaven's epilepsy treatment candidate, is slated for pivotal RISE3 Phase II/III trial results in the second half of 2026, serving as the company's most significant near-term catalyst. A recent downgrade from BofA Securities to Underperform has raised concerns about opakalim's differentiating potential in the competitive epilepsy market, particularly when compared to competing treatments.",
  "summary": null,
  "key_points": [
    "Biohaven reports narrowed loss of 75 cents per share for Q2 2025",
    "Company holds $351.8 million in cash and equivalents as of March 31",
    "Opakalim epilepsy drug data expected in second half of 2026"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}